M
Michael D. Prados
Researcher at University of California, San Francisco
Publications - 466
Citations - 57545
Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma
Nalin Gupta,Liliana Goumnerova,Peter E. Manley,Susan N. Chi,Donna Neuberg,Maneka Puligandla,Maneka Puligandla,Jason Fangusaro,Stewart Goldman,Stewart Goldman,Tadanori Tomita,Tord D. Alden,Arthur J. DiPatri,Joshua B. Rubin,Karen Gauvain,David D. Limbrick,Jeffrey R. Leonard,J. Russel Geyer,Sarah Leary,Samuel R. Browd,Zhihong Wang,Sandeep Sood,Anne Bendel,Anne Bendel,Mahmoud Nagib,Sharon Gardner,Matthias A. Karajannis,Matthias A. Karajannis,David H. Harter,Kanyalakshmi Ayyanar,William Gump,Daniel C. Bowers,Bradley E. Weprin,Tobey J. MacDonald,Dolly Aguilera,Barunashish Brahma,Nathan Robison,Erin Kiehna,Mark Krieger,Eric Sandler,Philipp R. Aldana,Ziad Khatib,John Ragheb,Sanjiv Bhatia,Sabine Mueller,Anu Banerjee,Amy Lee Bredlau,Sri Gururangan,Herbert E. Fuchs,Kenneth J. Cohen,George I. Jallo,Kathleen Dorris,Michael H. Handler,Melanie Comito,Mark S. Dias,Kellie J. Nazemi,Lissa C. Baird,Jeffrey R. Murray,Neal I. Lindeman,Jason L. Hornick,Hayley Malkin,Claire Sinai,Lianne Greenspan,Karen Wright,Karen Wright,Michael D. Prados,Pratiti Bandopadhayay,Keith L. Ligon,Mark W. Kieran +68 more
TL;DR: Surgical biopsy of DIPGs is technically feasible, associated with acceptable risks, and can provide biologic data that can inform treatment decisions, according to the authors.
Journal ArticleDOI
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab
Michael D. Prados,Timothy F. Cloughesy,Meghna Samant,Liang Fang,Patrick Y. Wen,Tom Mikkelsen,David Schiff,Lauren E. Abrey,W. K. Alfred Yung,Nina Paleologos,Martin K. Nicholas,Randy L. Jensen,James J. Vredenburgh,Asha Das,Henry S. Friedman +14 more
TL;DR: A landmark analysis was performed to evaluate the association between OR and survival at 9, 18, and 26 weeks for 167 patients with recurrent GBM who participated in BRAIN, a phase II trial that evaluated efficacy of bevacizumab alone or in combination with irinotecan.
Journal ArticleDOI
Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts
Pin Yuan Chen,Tomoko Ozawa,Daryl C. Drummond,Ashish Kalra,Jonathan Fitzgerald,Dmitri B. Kirpotin,Kuo Chen Wei,Nicholas Butowski,Michael D. Prados,Mitchel S. Berger,John Forsayeth,Krystof S. Bankiewicz,C. David James +12 more
TL;DR: Results indicate that liposomal formulation plus direct intratumoral administration of therapeutic are important for maximizing the anti-tumor effects of irinotecan and support clinical trial evaluation of this therapeutic plus route of administration combination.
Journal ArticleDOI
Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma
John G. Kuhn,Susan M. Chang,Patrick Y. Wen,Timothy F. Cloughesy,Harry S. Greenberg,David Schiff,Charles A. Conrad,Karen Fink,H. Ian Robins,Minesh P. Mehta,Lisa M. DeAngelis,Jeffrey J. Raizer,Kenneth R. Hess,Kathleen R. Lamborn,Janet Dancey,Michael D. Prados +15 more
TL;DR: Drugs that induce cytochrome P450 3A4, such as EIAEDs, significantly affect the pharmacokinetics of temsirolimus and its active metabolite, sirolimu, in patients receiving enzyme-inducing antiepileptic drugs (EIAED).
Journal ArticleDOI
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Nicholas Butowski,Susan M. Chang,Kathleen R. Lamborn,Mei Yin C. Polley,Russel O. Pieper,Joseph F. Costello,Scott R. VandenBerg,Rupa Parvataneni,Angelina Nicole,Patricia Sneed,Jennifer Clarke,Emily Hsieh,Bruno M. Costa,Rui Manuel Reis,Maria Hristova-Kazmierski,Steven J. Nicol,Donald Thornton,Michael D. Prados +17 more
TL;DR: OS and PFS results from the current trial were comparable to those from a prior phase II study using erlotinib and were significantly better than those from 2 other previous studies that used thalidomide or cis-retinoic acid, all in combination with temozolomide plus RT.